The shadow of generic challenges has consistently loomed over copyright’s famous drug, Viagra, sparking questions about the prospects of related drug investments. While early periods saw significant returns, the intellectual property expiration has opened the way for cheaper copies, possibly lowering revenue and creating a real danger for investo